# Sample Novel Variants Analysis Report
## OpenCRAVAT Pipeline Output Example

### Executive Summary

This is an example report generated by the OpenCRAVAT Novel Variants Discovery Pipeline. This template demonstrates the structure and format of analysis outputs without containing actual research data.

---

## üìä Dataset Overview

- **Total variants analyzed**: [Your dataset size]
- **Data source**: OpenCRAVAT annotated WES data
- **Annotation columns**: [Number of annotation fields]
- **Population context**: [Your target population]
- **Processing approach**: Chunk-based analysis

---

## üß¨ Methodology Summary

### Novel Variant Discovery Strategy

The pipeline identifies potentially pathogenic novel variants by:
- Avoiding reliance on ClinVar annotations
- Using population-specific scoring systems
- Integrating multiple computational predictors
- Applying frequency-based filtering

### Scoring Components

**Novel Variant Score Formula:**
```
Score = CADD_Component + REVEL_Component + Frequency_Component + 
        LoF_Bonus + Consensus_Score + Population_Specificity_Bonus
```

---

## üéØ Example Results

### Sample High-Scoring Variants

| Gene | Position | Type | Score | CADD | REVEL | Frequency | Status |
|------|----------|------|-------|------|-------|-----------|--------|
| GENE_A | chr1:123456 | missense | 75.2 | 32.1 | 0.95 | 1e-6 | Ultra-rare |
| GENE_B | chr2:234567 | missense | 72.8 | 30.5 | 0.92 | 5e-6 | Ultra-rare |
| GENE_C | chr3:345678 | missense | 70.4 | 29.8 | 0.88 | 1e-5 | Very rare |

*Note: These are example entries. Replace with your actual results.*

### Frequency Distribution Example

- **Ultra-rare variants**: [Number] (frequency <0.001%)
- **Very rare variants**: [Number] (frequency 0.001-0.01%)
- **Rare variants**: [Number] (frequency 0.01-1%)
- **Population-specific variants**: [Number]

---

## üî¨ Functional Analysis

### High-Impact Categories

**Loss-of-Function Variants:**
- Stop gained: [Number] variants
- Frameshift: [Number] variants  
- Splice site disruption: [Number] variants

**Damaging Missense Variants:**
- High CADD (>30): [Number] variants
- High REVEL (>0.8): [Number] variants
- PolyPhen2 probably damaging: [Number] variants

### Gene Function Categories

**Example affected gene families:**
- **Cardiac/muscle function**: [List relevant genes]
- **Metabolic enzymes**: [List relevant genes]
- **Ion transport**: [List relevant genes]
- **Immune signaling**: [List relevant genes]

---

## üåç Population Analysis

### Population-Specific Findings

**Target Population Results:**
- Total variants analyzed in [population]: [Number]
- Population-specific variants identified: [Number]
- Cross-population frequency differences: [Description]

**Clinical Implications:**
- Novel pathogenic candidates: [Number] variants
- Population-specific pharmacogenomic variants: [Number]
- Founder effect candidates: [Number]

---

## üìà Quality Metrics

### Computational Validation
- **Processing time**: [Duration] for [dataset size]
- **Memory usage**: [Peak memory] GB
- **Data completeness**: [Percentage]% variants with complete annotations

### Statistical Validation
- **Cross-database consistency**: [Correlation coefficient]
- **Multi-predictor agreement**: [Percentage]% consensus
- **Population stratification**: [Quality assessment]

---

## üéØ Clinical Prioritization

### Tier 1: Immediate Investigation
**[Number] variants** with scores >70 points
- High deleteriousness scores
- Ultra-rare frequencies
- Strong functional predictions

### Tier 2: High Priority
**[Number] variants** with scores 60-70 points
- Moderate to high pathogenicity predictions
- Rare frequencies
- Multiple predictor support

### Tier 3: Research Interest
**[Number] variants** with scores 50-60 points
- Population studies candidates
- Functional validation targets
- Research cohort inclusion

---

## üöÄ Recommendations

### Immediate Actions
1. **Functional validation** of top-scoring variants
2. **Clinical correlation** with phenotypes
3. **Family segregation** analysis
4. **Population replication** studies

### Future Directions
1. **Expand population analysis**
2. **Integrate additional data types**
3. **Develop clinical guidelines**
4. **Pharmacogenomic testing**

---

## üìù Data Files Generated

### Output Files
- `novel_variants_scored.csv`: All variants with scores
- `high_priority_variants.csv`: Top-tier candidates
- `population_specific_variants.csv`: Population-focused results
- `summary_statistics.txt`: Analysis summary

### Visualization Files
- `score_distribution.png`: Score distribution plot
- `frequency_analysis.png`: Population frequency analysis
- `gene_categories.png`: Functional category breakdown

---

## ‚ö†Ô∏è Important Notes

### Limitations
- Computational predictions require experimental validation
- Population databases have inherent biases
- Clinical interpretation requires domain expertise
- Results should be validated in independent cohorts

### Ethical Considerations
- Follow institutional review board guidelines
- Ensure appropriate consent for genetic analysis
- Consider genetic counseling for clinical applications
- Respect privacy and data sharing policies

---

## üìû Contact Information

For questions about this analysis or methodology:

**Analyst**: [Your Name]
**Institution**: [Your Institution]
**Email**: [Your Email]
**Date**: [Analysis Date]

---

**Analysis Software**: OpenCRAVAT Novel Variants Discovery Pipeline v1.0  
**Repository**: https://github.com/[username]/opencravat-novel-variants-pipeline  
**Documentation**: See `docs/methodology.md` for detailed methods 